An interventional study of Cervical lymphovenous anastomosis (LVA) and Cervical lymphovenous anastomosis (LVA) in Alzheimer and Alzheimer Dementia (AD), sponsored by University of Siena. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by University of Siena · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.
Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 169th largest by planned enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2026, is one of 54 with no phase, reaches primary completion later than 52 of the 71 other live ones, and was the 203rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
Exciva GmbH · Sites in Italy, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 47 · Phase 3 75 · Phase 4 2
First in 2003; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 328 across the 170 interventional studies, 273 across the 36 observational. Of the 125 that completed or were terminated, 64 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 206 have an industry lead sponsor. The 10 most frequent:
University of Siena is the lead sponsor of 65 studies on the registry; 15 are open to participants now.
University of Siena has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Alzheimer Disease with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06179680IRCCS Policlinico S. DonatoWhite Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease | 2026-12 |
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 206 studies in Alzheimer Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain. Recent evidence suggests that the glymphatic and meningeal lymphatic systems, which contribute to the removal of waste products from the brain, may play a role in AD. In particular, impaired drainage through the deep cervical lymphatic system may contribute to the accumulation of disease-related proteins.
The LymphDAD study is a prospective, single-center pilot study designed to explore whether surgically improving cervical lymphatic drainage may be associated with changes in biological markers, brain imaging, and cognitive and clinical measures in selected patients with AD who are not eligible for currently available disease-modifying treatments.
Five participants with AD will undergo a minimally invasive microsurgical procedure called lymphovenous anastomosis (LVA), in which small cervical lymphatic vessels are connected to nearby small veins to facilitate lymphatic drainage. During the procedure, a small sample of lymphatic fluid will also be collected for exploratory analysis of amyloid-beta and tau proteins.
Participants will undergo clinical and neuropsychological assessments, blood sampling, magnetic resonance imaging (MRI), and amyloid positron emission tomography (PET) before the procedure and during follow-up. Follow-up assessments will be performed at 1, 3, 6, and 12 months after surgery.
The study is exploratory and is not designed to demonstrate a definitive clinical benefit. Its primary purpose is to obtain preliminary information on the feasibility, safety, and possible biological and clinical effects of cervical LVA in AD, which may support the design of future controlled studies.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) and pathological tau, accompanied by neuronal loss and progressive cognitive impairment. Recent evidence suggests that the glymphatic and meningeal lymphatic systems contribute to the clearance of brain waste products, including Aβ and tau, and that impaired drainage through the deep cervical lymphatic system may be involved in AD pathophysiology.
Emerging preclinical and clinical evidence has suggested that restoration or enhancement of cervical lymphatic drainage may represent a potential therapeutic approach. Preliminary clinical studies have reported possible improvements in cognitive and clinical measures and favorable changes in AD-related biomarkers following cervical lymphatic surgery, although the available evidence remains limited and further prospective studies are needed.
The LymphDAD study is a prospective, single-center, pilot interventional study designed to explore the effects of restoring cervical lymphatic drainage in selected patients with AD who are not eligible for currently available disease-modifying therapies. Five participants will be enrolled.
All enrolled participants will undergo cervical lymphovenous anastomosis (LVA). LVA is a minimally invasive supermicrosurgical procedure in which patent lymphatic vessels are connected to small-caliber cervical veins to facilitate lymphatic drainage. The procedure will be performed under general anesthesia with indocyanine green fluorescence lymphography to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid will be collected intraoperatively from a lymphatic channel already exposed during the procedure for exploratory analysis of Aβ and tau.
The study will evaluate changes in circulating biomarkers, including Aβ42, Aβ40, phosphorylated tau (p-tau181 and p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Exploratory analyses of Aβ and tau in intraoperative lymphatic fluid will also be performed.
Neuroimaging assessments will include structural magnetic resonance imaging (MRI) for brain volumetry and amyloid positron emission tomography (PET) for assessment of amyloid burden. Clinical and cognitive outcomes will be assessed using standardized instruments, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Neuropsychiatric Inventory (NPI), Clinical Dementia Rating (CDR), and, when feasible, the EQ-5D quality-of-life questionnaire.
Assessments will be performed at baseline and during follow-up. Blood biomarkers will be assessed at baseline, 1 month, and 6 months. Cognitive and clinical assessments will be performed at baseline, 3, 6, and 12 months. MRI volumetry and amyloid PET will be repeated at 6 months.
The primary purpose of this pilot study is exploratory. Outcomes will be evaluated as changes from baseline within each participant. The study does not include a control group and is not designed to establish the efficacy of LVA or demonstrate a definitive clinical benefit. The results will provide preliminary information regarding the feasibility and safety of the procedure and its possible effects on biological, imaging, cognitive, and clinical parameters, supporting the design of future controlled clinical studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-arm pilot study will undergo cervical lymphovenous anastomosis (LVA), a minimally invasive supermicrosurgical procedure intended to enhance cervical lymphatic drainage. Patent cervical lymphatic vessels will be connected to small-caliber cervical venous branches under high magnification, with indocyanine green (ICG) fluorescence lymphography used to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid will be collected intraoperatively for exploratory analysis of amyloid-beta and tau biomarkers. Participants will continue standard-of-care treatment for Alzheimer's disease and other comorbidities throughout the study.
Procedure: Cervical lymphovenous anastomosis (LVA)
Microsurgical restoration of cervical lymphatic drainage by connecting patent lymphatic channels to small-caliber cervical venous branches. The procedure is performed along the posterior edge of the sternocleidomastoid muscle using supermicrosurgical techniques. Indocyanine green (ICG) fluorescence lymphography is used to identify lymphatic vessels and assess anastomotic flow. A small sample of lymphatic fluid is collected intraoperatively from a lymphatic channel already exposed during the procedure for exploratory analysis of amyloid-beta and tau biomarkers.
Microsurgical restoration of cervical lymphatic drainage by connecting patent lymphatic channels to small-caliber cervical venous branches. In this study, lymphovenous anastomoses will be created along the posterior edge of the sternocleidomastoid muscle using supermicrosurgical techniques. Indocyanine green (ICG) fluorescence lymphography will guide lymphatic identification and assess anastomotic patency. A small sample of lymphatic fluid will also be collected intraoperatively from an exposed lymphatic channel for exploratory biomarker analysis.
Change from baseline in plasma amyloid-beta concentrations
Change from baseline in plasma amyloid-beta 42 (Aβ42) and amyloid-beta 40 (Aβ40) concentrations following cervical lymphovenous anastomosis (LVA).
Time frame: Baseline, 1 month, and 6 months after LVA
Change from baseline in plasma phosphorylated tau concentrations
Change from baseline in plasma phosphorylated tau 181 (p-tau181) and phosphorylated tau 217 (p-tau217) concentrations following cervical LVA.
Time frame: Baseline, 1 month, and 6 months after LVA
Change from baseline in plasma NfL and GFAP concentrations
Change from baseline in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) concentrations following cervical LVA.
Time frame: Baseline, 1 month, and 6 months after LVA
Change from baseline in Mini-Mental State Examination score
Change in Mini-Mental State Examination (MMSE) score from baseline. The MMSE ranges from 0 to 30, with higher scores indicating better cognitive function.
Time frame: Baseline to 3, 6, and 12 months after LVA
Change from baseline in Montreal Cognitive Assessment score
Change in Montreal Cognitive Assessment (MoCA) score from baseline. The MoCA ranges from 0 to 30, with higher scores indicating better cognitive function.
Time frame: Baseline to 3, 6, and 12 months after LVA
Change from baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale score
Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score from baseline. Scores range from 0 to 70, with higher scores indicating greater cognitive impairment.
Time frame: Baseline to 3, 6, and 12 months after LVA
Change from baseline in Neuropsychiatric Inventory score
Change in Neuropsychiatric Inventory (NPI) total score from baseline. Scores range from 0 to 144, with higher scores indicating greater neuropsychiatric symptom burden.
Time frame: Baseline to 3, 6, and 12 months after LVA
Change from baseline in Clinical Dementia Rating score
Change in Clinical Dementia Rating (CDR) global score from baseline. The CDR global score ranges from 0 to 3, with higher scores indicating greater dementia severity.
Time frame: Baseline to 3, 6, and 12 months after LVA
Change from baseline in hippocampal volume on magnetic resonance imaging
Change from baseline in automated hippocampal volume measured on structural magnetic resonance imaging (MRI).
Time frame: Baseline and 6 months after LVA
Change from baseline in cortical gray-matter volume on magnetic resonance imaging
Change from baseline in automated cortical gray-matter volume measured on structural magnetic resonance imaging (MRI).
Time frame: Baseline and 6 months after LVA
Change from baseline in amyloid PET standardized uptake value ratio
Change from baseline in global and regional cerebral amyloid burden quantified using standardized uptake value ratio (SUVr) on amyloid positron emission tomography (PET).
Time frame: Baseline and 6 months after LVA
Change from baseline in amyloid PET Centiloid value
Change from baseline in cerebral amyloid burden quantified using the Centiloid scale on amyloid positron emission tomography (PET).
Time frame: Baseline and 6 months after LVA
Number of participants with procedure-related adverse events
Number of participants experiencing one or more adverse events considered related to cervical lymphovenous anastomosis, including infection, hematoma, wound-healing complications, transient swelling, neurological deficits, or anastomotic thrombosis or failure.
Time frame: From LVA through 12 months after surgery
Number of participants with patent lymphovenous anastomosis
Number of participants with intraoperative evidence of lymphovenous anastomotic patency demonstrated by indocyanine-green fluorescence lymphography.
Time frame: During the LVA procedure
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Siena